GHRMSA
Mulhouse, 68100, France
NCT Number: NCT05485090
The main objective of this study is to adapt the Canadian French version of the safety assessment scale for use in France. The Safety Assessment Scale was developped for community healthcare providers working with elderly people with dementia who are being cared for at home, to assess the risk of accidents. The short version of the Safety Assessment Scale is a screening tool and the longer version provides an in-depth evaluation of safety.
This scale is a risk assessment grid for accidents and injuries at home for elderly people with major neurocognitive disorders, available in English and French (Canadian). There are two versions:
* The short version is used for screening. A score of 11 to 14 indicates a moderate risk of injury, while a score ≥ 15 indicates a high risk of injury; * The long version is used for in-depth assessment when the score on the short version indicates a moderate or high risk of injury. The questionnaire is divided into nine sections:
1. Caregiver and environment, 2/smoking, 3/fire and burns, 4/nutrition, 5/food poisoning and toxic substances, 6/medication and health problems, 7/wandering and adaptation to temperature changes, 8/trauma, and 9/driving.
The short version includes some of the questions from sections 1 to 7 of the long version.
Looking for future studies?
Notify Me60 year and older
All sexes
Observational
Mulhouse, 68100, France
Secondary objectives:
The other objectives of this study are to assess the test-retest reliability and the inter-rater reliability of the translated scale and to evaluate the internal consistency of the long version of the translated scale.
Conduct of research:
Caregivers of patients with major neurocognitive disorders included in the study will complete the adapted scale with an investigator. A pre-test phase will be carried out with 10 caregivers: the caregivers will complete the questionnaire only once with an investigator.
After this phase, the translated Safety Assessment Scale will be corrected if there are difficulties in understanding certain words or sentences. The new scale will then be evaluated on two cohorts of 53 caregivers (cohort 1: caregivers will complete the adapted scale twice with the same investigator; cohorte 2: caregivers will complete the adapted scale twice with two different investigators).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
Time frame: 10 days
The caregiver will complete the questionnaire (adapted Safety Assessment Scale) twice with the same investigator
Time frame: 10 days
The caregiver will complete the questionnaire (adapted Safety Assessment Scale) twice with two different investigators.
Time frame: 10 days
The internal consistency of the items will be evaluated within each of the 9 sections of the scale by calculating the Cronbach's alpha coefficient.
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Other
Cross-cultural Adaptation Into French of the Safety Assessment Scale for Elderly People With a Major Neurocognitive Disorder Living at Home.
Acronym: ESTRAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04664920
Behavior, Brain Diseases
Leuven, Vlaams Brabant, Belgium
View Trial DetailsNCT06615167
Brain Diseases, Central Nervous System Diseases
Chuncheon, Gangwon-do, South Korea
View Trial DetailsNCT05571553
Frailty, Major Neurocognitive Disorder
Montreal, Quebec, Canada
View Trial DetailsNCT06701630
Cognition Disorders, Cognitive Dysfunction
Milan, Michigan, Italy
View Trial Details